A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

NCT00165633 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Menatetrenone
DRUG: Menatetrenone
DRUG: Placebo

Sponsor

Eisai Limited